{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:45:38Z","timestamp":1779281138559,"version":"3.51.4"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000777","name":"University of Leeds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000777","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["11723"],"award-info":[{"award-number":["11723"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"CRUK","doi-asserted-by":"crossref","award":["A20105"],"award-info":[{"award-number":["A20105"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.smim.2019.101295","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T17:10:13Z","timestamp":1570554613000},"page":"101295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications"],"prefix":"10.1016","volume":"42","author":[{"given":"Janna","family":"Krueger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher E.","family":"Rudd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2019.101295_bib0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","article-title":"Immune modulation in Cancer with antibodies","volume":"65","author":"Page","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.smim.2019.101295_bib0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for Cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2019.101295_bib0015","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2019.101295_bib0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu. Rev. Immunol."},{"issue":"19","key":"10.1016\/j.smim.2019.101295_bib0025","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.smim.2019.101295_bib0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity."},{"key":"10.1016\/j.smim.2019.101295_bib0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"5502","key":"10.1016\/j.smim.2019.101295_bib0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science."},{"issue":"2","key":"10.1016\/j.smim.2019.101295_bib0045","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.immuni.2016.01.018","article-title":"Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses","volume":"44","author":"Taylor","year":"2016","journal-title":"Immunity."},{"key":"10.1016\/j.smim.2019.101295_bib0050","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3389\/fimmu.2017.01653","article-title":"Glycogen Synthase Kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8+ cytotoxic T-Cells: implications for anti-PD-1 Immunotherapy","volume":"8","author":"Taylor","year":"2017","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.smim.2019.101295_bib0055","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/0008-5472.CAN-17-0491","article-title":"Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy","volume":"78","author":"Taylor","year":"2018","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.smim.2019.101295_bib0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","article-title":"The PD-1-PD-L pathway in immunological tolerance","volume":"27","author":"Okazaki","year":"2006","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.smim.2019.101295_bib0065","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0952-7915(02)00398-9","article-title":"New regulatory co-receptors: inducible co-stimulator and PD-1","volume":"14","author":"Okazaki","year":"2002","journal-title":"Curr. Opin. Immunol."},{"issue":"12","key":"10.1016\/j.smim.2019.101295_bib0070","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"A third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.smim.2019.101295_bib0075","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity","volume":"9","author":"Curiel","year":"2003","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.smim.2019.101295_bib0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity."},{"issue":"5","key":"10.1016\/j.smim.2019.101295_bib0085","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1084\/jem.20130790","article-title":"RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance","volume":"211","author":"Xiao","year":"2014","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.smim.2019.101295_bib0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2019.101295_bib0095","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.193.7.839","article-title":"B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells","volume":"193","author":"Tseng","year":"2001","journal-title":"J. Exp. Med."},{"issue":"24","key":"10.1016\/j.smim.2019.101295_bib0100","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2019.101295_bib0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nri727","article-title":"The B7\u2013-CD28 superfamily","volume":"2","author":"Sharpe","year":"2002","journal-title":"Nature Rev Immunol"},{"issue":"2","key":"10.1016\/j.smim.2019.101295_bib0110","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.smim.2019.101295_bib0115","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nri1202","article-title":"The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease","volume":"3","author":"Engel","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.smim.2019.101295_bib0120","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/blood-2002-02-0445","article-title":"The role of SAP in murine CD150 (SLAM)-mediated T-cell proliferation and interferon gamma production","volume":"100","author":"Howie","year":"2002","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.smim.2019.101295_bib0125","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int. Immunol."},{"issue":"7077","key":"10.1016\/j.smim.2019.101295_bib0130","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature."},{"issue":"5","key":"10.1016\/j.smim.2019.101295_bib0135","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","article-title":"Coinhibitory pathways in the B7-CD28 ligand-receptor family","volume":"44","author":"Schildberg","year":"2016","journal-title":"Immunity."},{"issue":"6","key":"10.1016\/j.smim.2019.101295_bib0140","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2019.101295_bib0145","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1128\/JVI.02524-08","article-title":"Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection","volume":"83","author":"Blattman","year":"2009","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.smim.2019.101295_bib0150","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1084\/jem.20071949","article-title":"Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection","volume":"205","author":"Ha","year":"2008","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.smim.2019.101295_bib0155","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2010-12-328070","article-title":"Responsiveness of HIV-specific CD4 t cells to PD-1 blockade","volume":"118","author":"Porichis","year":"2011","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.smim.2019.101295_bib0160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.smim.2019.101295_bib0165","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1084\/jem.20061800","article-title":"Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade","volume":"203","author":"Freeman","year":"2006","journal-title":"J. Exp. Med."},{"issue":"7109","key":"10.1016\/j.smim.2019.101295_bib0170","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature."},{"issue":"3","key":"10.1016\/j.smim.2019.101295_bib0175","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/hep.22419","article-title":"Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion","volume":"48","author":"Evans","year":"2008","journal-title":"Hepatology."},{"issue":"4","key":"10.1016\/j.smim.2019.101295_bib0180","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/jvh.12009","article-title":"PD-1 expression on CTL may be related to more severe liver damage in CHB patients with HBV genotype C than in those with genotype B infection","volume":"20","author":"Xibing","year":"2013","journal-title":"J. Viral Hepat."},{"issue":"7235","key":"10.1016\/j.smim.2019.101295_bib0185","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.smim.2019.101295_bib0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.smim.2019.101295_bib0195","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"8","key":"10.1016\/j.smim.2019.101295_bib0200","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.smim.2019.101295_bib0205","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.smim.2019.101295_bib0210","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to Cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.smim.2019.101295_bib0215","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.11.017","article-title":"The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience","volume":"148","author":"Berman","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.smim.2019.101295_bib0220","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm.2232","article-title":"Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF","volume":"16","author":"Quigley","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2019.101295_bib0225","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.smim.2019.101295_bib0230","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.2106","article-title":"Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection","author":"Said","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2019.101295_bib0235","doi-asserted-by":"crossref","first-page":"13110","DOI":"10.1038\/srep13110","article-title":"Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung Cancer","volume":"5","author":"He","year":"2015","journal-title":"Sci. Rep."},{"issue":"26","key":"10.1016\/j.smim.2019.101295_bib0240","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7528","key":"10.1016\/j.smim.2019.101295_bib0245","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.smim.2019.101295_bib0250","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-Cell lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10066","key":"10.1016\/j.smim.2019.101295_bib0255","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet."},{"issue":"22","key":"10.1016\/j.smim.2019.101295_bib0260","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.smim.2019.101295_bib0265","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40425-017-0310-x","article-title":"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after \u22651 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial","volume":"6","author":"Kaufman","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"19","key":"10.1016\/j.smim.2019.101295_bib0270","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","volume":"35","author":"Lee","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.smim.2019.101295_bib0275","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jcma.2016.08.005","article-title":"Immune checkpoint inhibitors for nonsmall cell lung cancer treatment","volume":"80","author":"Chen","year":"2017","journal-title":"J. Chin. Med. Assoc."},{"issue":"6230","key":"10.1016\/j.smim.2019.101295_bib0280","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science."},{"issue":"19","key":"10.1016\/j.smim.2019.101295_bib0285","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of Pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.smim.2019.101295_bib0290","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1432-1033.1980.tb06059.x","article-title":"Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase","volume":"107","author":"Embi","year":"1980","journal-title":"European journal of biochemistry \/ FEBS"},{"issue":"8","key":"10.1016\/j.smim.2019.101295_bib0295","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/j.1460-2075.1990.tb07419.x","article-title":"Molecular cloning and expression of glycogen synthase kinase-3\/factor","volume":"9","author":"Woodgett","year":"1990","journal-title":"A. Embo J."},{"issue":"Pt 1","key":"10.1016\/j.smim.2019.101295_bib0300","first-page":"1","article-title":"GSK3 takes centre stage more than 20 years after its discovery","volume":"359","author":"Frame","year":"2001","journal-title":"Biochem. J."},{"issue":"5","key":"10.1016\/j.smim.2019.101295_bib0305","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1046\/j.1471-4159.2002.00918.x","article-title":"Alternative splicing isoform of tau protein kinase I\/glycogen synthase kinase 3beta","volume":"81","author":"Mukai","year":"2002","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.smim.2019.101295_bib0310","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(94)90334-4","article-title":"Signal transduction by lymphocyte antigen receptors","volume":"76","author":"Weiss","year":"1994","journal-title":"Cell."},{"issue":"1","key":"10.1016\/j.smim.2019.101295_bib0315","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0092-8674(00)80953-8","article-title":"Adaptors and molecular scaffolds in immune cell signaling","volume":"96","author":"Rudd","year":"1999","journal-title":"Cell."},{"issue":"14","key":"10.1016\/j.smim.2019.101295_bib0320","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1073\/pnas.85.14.5190","article-title":"The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes","volume":"85","author":"Rudd","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.smim.2019.101295_bib0325","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1073\/pnas.86.9.3277","article-title":"The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex","volume":"86","author":"Barber","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6212","key":"10.1016\/j.smim.2019.101295_bib0330","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/338257a0","article-title":"Signal transduction through the CD4 receptor involves the activation of the internal membrane tyrosine-protein kinase p56lck","volume":"338","author":"Veillette","year":"1989","journal-title":"Nature."},{"issue":"4","key":"10.1016\/j.smim.2019.101295_bib0335","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0092-8674(92)90598-7","article-title":"ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain","volume":"71","author":"Chan","year":"1992","journal-title":"Cell."},{"key":"10.1016\/j.smim.2019.101295_bib0340","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev.immunol.20.092601.111357","article-title":"Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins","volume":"20","author":"Samelson","year":"2002","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2019.101295_bib0345","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/eji.1830210712","article-title":"Biochemical identification of a direct physical interaction between the CD4:p56lck and Ti(TcR)\/CD3 complexes","volume":"21","author":"Burgess","year":"1991","journal-title":"Eur. J. Immunol."},{"issue":"Pt 7","key":"10.1016\/j.smim.2019.101295_bib0350","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1242\/jcs.00384","article-title":"GSK-3: tricks of the trade for a multi-tasking kinase","volume":"116","author":"Doble","year":"2003","journal-title":"J. Cell. Sci."},{"issue":"6","key":"10.1016\/j.smim.2019.101295_bib0355","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1476-5381.2008.00085.x","article-title":"Glycogen synthase kinase 3: more than a namesake","volume":"156","author":"Rayasam","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.smim.2019.101295_bib0360","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.smim.2019.101295_bib0365","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S1097-2765(01)00253-2","article-title":"A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation","volume":"7","author":"Frame","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.smim.2019.101295_bib0370","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0301-0082(01)00011-9","volume":"65","author":"Aea","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.smim.2019.101295_bib0375","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2011.00032","article-title":"GSK-3 inhibitors: preclinical and focus on CNS","author":"Eldar-Finkelman","year":"2011","journal-title":"Front. Mol. Neurosci."},{"issue":"10","key":"10.1016\/j.smim.2019.101295_bib0380","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/35096075","article-title":"The renaissance of GSK3","volume":"2","author":"Cohen","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.smim.2019.101295_bib0385","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.192.1.99","article-title":"Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3","volume":"192","author":"Ohteki","year":"2000","journal-title":"J. Exp. Med."},{"issue":"43","key":"10.1016\/j.smim.2019.101295_bib0390","doi-asserted-by":"crossref","first-page":"32385","DOI":"10.1074\/jbc.M604878200","article-title":"TcR and TcR-CD28 engagement of protein kinase B (PKB\/AKT) and glycogen synthase kinase-3 (GSK-3) operates independently of guanine nucleotide exchange factor VAV-1","volume":"281","author":"Wood","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.smim.2019.101295_bib0395","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.4049\/jimmunol.168.6.2729","article-title":"CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K\/PKB signaling pathway in primary human T cells","volume":"168","author":"Appleman","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2019.101295_bib0400","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1126\/science.275.5308.1930","article-title":"Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3","volume":"275","author":"Beals","year":"1997","journal-title":"Science."},{"issue":"276","key":"10.1016\/j.smim.2019.101295_bib0405","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1074\/jbc.M004888200","article-title":"Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc","author":"Neal","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.smim.2019.101295_bib0410","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.smim.2019.101295_bib0415","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ni.2046","article-title":"Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection","volume":"12","author":"Kao","year":"2011","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2019.101295_bib0420","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/icb.2012.53","article-title":"Notch signaling regulates PD-1 expression during CD8(+) T-cell activation","volume":"91","author":"Mathieu","year":"2013","journal-title":"Immunol. Cell Biol."},{"issue":"7","key":"10.1016\/j.smim.2019.101295_bib0425","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","article-title":"NFATc1 regulates PD-1 expression upon T cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2019.101295_bib0430","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity","volume":"186","author":"Terawaki","year":"2011","journal-title":"J. Immunol."},{"issue":"20","key":"10.1016\/j.smim.2019.101295_bib0435","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1158\/0008-5472.CAN-17-0799","article-title":"GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity","volume":"77","author":"Cichocki","year":"2017","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.smim.2019.101295_bib0440","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nm.1982","article-title":"Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells","volume":"15","author":"Gattinoni","year":"2009","journal-title":"Nat. Med."},{"issue":"6332","key":"10.1016\/j.smim.2019.101295_bib0445","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science."},{"issue":"6332","key":"10.1016\/j.smim.2019.101295_bib0450","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science."},{"issue":"4","key":"10.1016\/j.smim.2019.101295_bib0455","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.immuni.2017.04.003","article-title":"Two strings in one bow: PD-1 negatively regulates via Co-receptor CD28 on t cells","volume":"46","author":"Krueger","year":"2017","journal-title":"Immunity."},{"issue":"1","key":"10.1016\/j.smim.2019.101295_bib0460","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.smim.2019.101295_bib0465","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3389\/fimmu.2017.01653","article-title":"Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8(+) cytotoxic T-Cells: implications for anti-PD-1 immunotherapy","volume":"8","author":"Taylor","year":"2017","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.smim.2019.101295_bib0470","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"issue":"21","key":"10.1016\/j.smim.2019.101295_bib0475","doi-asserted-by":"crossref","first-page":"30323","DOI":"10.18632\/oncotarget.8730","article-title":"Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)","volume":"7","author":"Zak","year":"2016","journal-title":"Oncotarget."},{"issue":"9","key":"10.1016\/j.smim.2019.101295_bib0480","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/13543776.2018.1512706","article-title":"A patent review on PD-1\/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)","volume":"28","author":"Shaabani","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"issue":"5","key":"10.1016\/j.smim.2019.101295_bib0485","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2019.101295_bib0490","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.smim.2019.101295_bib0495","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of Neoantigen Landscape during immune checkpoint blockade in non-small cell lung Cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.smim.2019.101295_bib0500","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1073\/pnas.1712107115","article-title":"Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion","volume":"115","author":"Avery","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.smim.2019.101295_bib0505","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1158\/1078-0432.CCR-16-2677","article-title":"Timing of PD-1 blockade is critical to effective combination immunotherapy with Anti-OX40","volume":"23","author":"Messenheimer","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"6264","key":"10.1016\/j.smim.2019.101295_bib0510","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"Vetizou","year":"2015","journal-title":"Science."},{"issue":"6371","key":"10.1016\/j.smim.2019.101295_bib0515","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science."},{"key":"10.1016\/j.smim.2019.101295_bib0520","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2017.01.001","article-title":"Second- and third-generation drugs for immuno-oncology treatment-The more the better?","volume":"74","author":"Dempke","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"16","key":"10.1016\/j.smim.2019.101295_bib0525","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1002\/anie.201707816","article-title":"Small molecules drive big improvements in immuno-oncology therapies","volume":"57","author":"Huck","year":"2018","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"15_suppl","key":"10.1016\/j.smim.2019.101295_bib0530","article-title":"Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas","volume":"35","author":"Lee","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.smim.2019.101295_bib0535","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532319300260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532319300260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:14:14Z","timestamp":1760915654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532319300260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":107,"alternative-id":["S1044532319300260"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2019.101295","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2019.101295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101295"}}